Neuromuscular Disorders
Volume 20, Issue 3 , Pages 192-197 , March 2010

Microvasculopathic neuromuscular diseases: Lessons from hypoxia-inducible factors

  • Stefan Probst-Cousin

      Affiliations

    • Department of Neurology, Klinikum Bremen-Ost, Züricher Straße 40, D-28325 Bremen, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 421 40861529; fax: +49 421 408 2462.
    • ,
  • Bernhard Neundörfer

      Affiliations

    • Department of Neurology, Friedrich-Alexander-University Erlangen-Nuremberg, Schwabachanlage 6, D-91054 Erlangen, Germany
    • ,
  • Dieter Heuss

      Affiliations

    • Department of Neurology, Friedrich-Alexander-University Erlangen-Nuremberg, Schwabachanlage 6, D-91054 Erlangen, Germany

Received 6 September 2009 ,Revised 21 December 2009 ,Accepted 7 January 2010.

References 

  1. Hohlfeld R. Dysimmune myopathies. Definition of entities and experimental models of myositis. In:  Karpati G editors. Structural and molecular basis of skeletal muscle diseases. Basel: ISN Neuropath Press; 2002;p. 218–220
  2. Hohlfeld R. Polymyositis and dermatomyositis. In:  Karpati G editors. Structural and molecular basis of skeletal muscle diseases. Basel: ISN Neuropath Press; 2002;p. 221–227
  3. Limaye VS, Blumbergs P, Roberts-Thomson PJ. Idiopathic inflammatory myopathies. Intern. Med. J. 2009;39:179–190
  4. Collins MP, Mendell JR, Periquet MI, et al. Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology. 2000;55:636–643
  5. Engelhard A, Lörler H, Neundörfer B. Immunohistochemical findings in vasculitic neuropathies. Acta Neurol. Scand. 1993;87:318–321
  6. Kissel JT, Riethmann JL, Omerza J. Peripheral nerve vasculitis: immune characterization of the vascular lesions. Ann. Neurol. 1989;25:291–297
  7. Cupps TR, Fauci AS. The vasculitides. Major Probl. Intern. Med. 1981;21:1–211
  8. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–192
  9. Carpenter S, Karpati G. Inflammatory myopathies. In: Carpenter S, Karpati G editors. Pathology of skeletal muscle. 2nd ed., Oxford: Oxford University Press; 2001. p. 542–543.
  10. Kernohan JW, Woltman HW. Periarteritis nodosa. A clinicopathologic study with special reference to the nervous system. Arch. Neurol. Psych. 1938;39:655–686
  11. Midroni G, Bilbao JM. Vasculitic neuropathy. In:  Midroni G,  Bilbao JM editor. Biopsy diagnosis of peripheral neuropathy. Boston: Butterworth-Heinemann; 1995;p. 241–262
  12. Heuss D, Probst-Cousin S, Kaiser C, Neundörfer B. Cell death in vasculitic neuropathy. Muscle Nerve. 2000;23:999–1004
  13. Satoi H, Oka N, Kawasaki T, Miyamoto K, Akiguchi I, Kimura J. Mechanisms of tissue injury in vasculitic neuropathies. Neurology. 1998;50:492–496
  14. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA. 1995;92:5510–5514
  15. Hofer T, Wenger RH, Gassmann M. Oxygen sensing, HIF-1α stabilization and potential therapeutic strategies. Pflügers Arch. Eur. J. Physiol. 2002;443:503–507
  16. Gassmann M, Wenger RH. HIF-1, a mediator of the molecular response to hypoxia. News Physiol. Sci. 1997;12:214–218
  17. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999;100:468–474
  18. Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br. J. Dermatol. 1998;139:1049–1051
  19. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–982
  20. Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr. Opin. Neurol. 2004;17:561–567
  21. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N. Engl. J. Med. 2000;342:626–633
  22. Rissanen TT, Vajanto I, Hiltunen MO, et al. Expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in ischemic skeletal muscle and its regeneration. Am. J. Pathol. 2002;160:1393–1403
  23. Stroka DM, Burkhardt T, Desbaillets I, et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 2001;15:2445–2453
  24. Oka N, Kawasaki T, Mitzutani K, Sugiyama H, Akiguchi I. Hypoxia-inducible factor 1α may be a marker for vasculitic neuropathy. Neuropathology. 2009;27:509–515
  25. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc. Natl. Acad. Sci. USA. 1993;90:4304–4308
  26. Konttinen YT, Mackiewicz Z, Povilenaite D, Sukura A, Hukkanen M, Virtanen I. Disease-associated increased HIF-1, avβ3 integrin, and Flt-1 do not suffice to compensate the damage-inducing loss of blood vessels in inflammatory myopathies. Rheumatol. Int. 2004;24:333–339
  27. Tian H, McKnight SL, Russel DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 1997;11:72–82
  28. Wiesener MS, Jürgensen JS, Rosenberger C, et al. Widespread, hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs. FASEB J. 2003;17:271–273
  29. Grange RW, Meeson A, Chin E, et al. Functional and molecular adaptations in skeletal muscle of myoglobin-mutant mice. Am. J. Physiol. Cell Physiol. 2001;281:C1487–1494
  30. Kappel A, Rönicke V, Damert A, Flamme I, Risau W, Breier G. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood. 1999;93:4284–4292
  31. O’Rourke JF, Tian YM, Ratcliffe PJ, Pugh CW. Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor 1α. J. Biol. Chem. 1999;274:2060–2071
  32. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fuji-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. USA. 1997;94:4273–4278
  33. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996;16:4604–4613
  34. Shima DT, Kuroki M, Deutsch U, Ng YS, Adamis AP, D’Amore PA. The mouse gene for vascular endothelial growth factor: genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J. Biol. Chem. 1996;271:3877–3883
  35. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9–22
  36. Kalka C, Masuda H, Takahashi T, et al. Vascular endothelial growth factor (165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ. Res. 2000;86:1198–1202
  37. Grundtman C, Tham E, Ulfgren AK, Lundberg IE. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum. 2008;58:3224–3238
  38. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. 2003;228:1–14
  39. Yasuda Y, Fulita Y, Musha T, et al. Expression of erythropoietin in human female reproductive organs. Ital. J. Anat. Embryol. 2001;106:215–222
  40. Junk AK, Mammis A, Savitz SI, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc. Natl. Acad. Sci. USA. 2002;99:10659–10664
  41. Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr. Suppl. 2002;91:36–42
  42. Augustin HG. Angiogenesis research – Quo vadis? (in German). Ophthalmologe. 2003;100:104–110
  43. Hoke A, Sun HS, Gordon T, Zochodne DW. Do denervated peripheral nerve trunks become ischemic? The impact of chronic denervation on vasa nervorum. Exp. Neurol. 2001;172:398–406
  44. Schratzberger P, Schratzberger G, Silver M, et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat. Med. 2000;6:405–413
  45. Cherwek DH, Hopkins MB, Thompson MJ, Annex BH, Taylor DA. Fiber type-specific differential expression of angiogenic factors in response to chronic hindlimb ischemia. Am. J. Physiol. Heart Circ. Physiol. 2000;279:932–938
  46. Gustafsson T, Knutsson A, Puntschart A, et al. Increased expression of vascular endothelial growth factor in human skeletal muscle in response to short-term one-legged exercise training. Pflügers Arch. 2003;444:752–759
  47. Gustafsson T, Puntschart A, Kaijser L, Jansson E, Sundberg CJ. Exercise-induced expression of angiogenesis-related transcription and growth factors in human skeletal muscle. Am. J. Physiol. Heart Circ. Physiol. 1999;45:H679–H685
  48. Wagner PD. Skeletal muscle angiogenesis. A possible role for hypoxia. Adv. Exp. Med. Biol. 2001;502:21–38
  49. Nagaraju K, Rider LG, Fan C, et al. Endothelial cell activation and neovascularization are prominent in dermatomyositis. J. Autoimmune Dis. 2006;3:2
  50. Carvalho JF, Blank M, Shoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimmune diseases. J. Clin. Immunol. 2007;27:246–256
  51. Springer ML, Chen AS, Kraft PE, Bednarski M, Blau HM. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol. Cell. 1998;2:549–558
  52. Khan TA, Sellke FW, Laham RJ. Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther. 2003;10:285–291
  53. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology. 2007;69:2008–2019
  54. Hohlfeld R, Dornmair K. Revisiting the immunopathogenesis of the inflammatory myopathies. Neurology. 2007;69:1966–1967

PII: S0960-8966(10)00018-0

doi: 10.1016/j.nmd.2010.01.005

Neuromuscular Disorders
Volume 20, Issue 3 , Pages 192-197 , March 2010

Article Tools

* Image Usage & Resolution